TG THERAPEUTICS, INC. (TGTX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, TG THERAPEUTICS, INC. reported revenue of $616.29M, up 87.3% from the prior year. The company was profitable, with a net margin of 72.6%. It held $1.06B in total assets against $415.23M in total liabilities.
Key ratios (FY2025)
20.0%
Operating margin
72.6%
Net margin
69.0%
Return on equity
+87.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M | — | — | — | — | — |
| Cost of Revenue | $100.71M | $38.49M | $14.13M | $265.0K | $790.0K | — | — | — | — | — |
| Operating Income | $123.32M | $41.93M | $20.63M | -$218.32M | -$344.77M | -$273.59M | -$169.06M | -$174.40M | -$118.71M | -$78.97M |
| Net Income | $447.18M | $23.38M | $12.67M | -$223.81M | -$348.10M | — | — | — | — | — |
| EPS (Diluted) | $2.77 | $0.15 | $0.09 | $-1.65 | $-2.63 | $-2.42 | — | — | — | — |
| Total Assets | $1.06B | $577.69M | $329.59M | $193.57M | $379.63M | $625.64M | $163.01M | $83.62M | $97.38M | $54.78M |
| Total Liabilities | $415.23M | $355.33M | $169.09M | $134.99M | $142.48M | $106.29M | $124.40M | $59.58M | $30.39M | $18.91M |
| Shareholders' Equity | $648.02M | $222.36M | $160.50M | $58.59M | $237.15M | $519.35M | — | — | — | — |
| Cash & Equivalents | $79.15M | $179.89M | $92.93M | $102.30M | $298.89M | $553.44M | $112.64M | $41.96M | $56.72M | $25.03M |
| Operating Cash Flow | -$24.77M | -$40.52M | -$31.41M | -$176.17M | -$295.63M | -$214.51M | -$132.81M | -$128.93M | -$93.76M | — |
| Capital Expenditures | $214.0K | $45.0K | $0 | $14.0K | $401.0K | $357.0K | $131.0K | $90.0K | $2.0K | $344.0K |
| Shares Outstanding | 155.31M | 155.84M | 151.42M | 146.39M | 143.25M | 140.58M | 109.38M | 83.87M | 73.14M | 56.78M |